Clinical Trial Litigation

The WSJ Law Blog has a good rundown of the potential exposure to Pfizer relating to the shutdown of clinical trials on its HDL-elevating drug Torcetrapib.  As you’d expect, there’s both potential tort litigation (though the clinical trial releases are likely broad enough to protect against most of that) and securities litigation.

Update: FDA has its press release up.